FINHUB Insights

RVTY · Q4 FY25 · Sep 29 – Dec 28, 2025

Revvity Q4 FY25: where the revenue came from and where it went

Revvity Q4 FY25: revenue $0.8B (+6% year over year). Net profit $0.1B. Largest cohort Diagnostics $0.4B. The whole income statement as a sankey diagram from the SEC filing.

Period
Sep 29 – Dec 28, 2025
Reported
Feb 24, 2026 10-K
Sankey diagram of Revvity's income statement for Q4 FY25: revenue of $0.8 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$0.8B +6% year over year
Operating profit$0.1B 14% margin
Net profit$0.1B 13% margin

The numbers

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 28, 2025).
ItemValueShare of revenueYear over year
Revenue 0.8 100% +6%
Diagnostics 0.4 50% +10%
Life Sciences 0.4 50% +2%
Research & development−0.18%+1pp
SG&A−0.333%−1pp
Other−0.345%+0pp
Operating profit0.114% margin−2pp
Net profit0.113%+0pp
Filing on EDGAR More quarters of RVTY

Source of the numbers: structured XBRL data from the filing (10-K). The diagram is generated automatically and checked against EDGAR before release. The fourth quarter has no column of its own in an annual report, so it is the full year minus the first nine months. How we calculate it → About and methodology.

Older quarters